List of Publications using SCH 79797 dihydrochloride (Axon 1275) purchased from Axon Medchem  

(Total 23 publication citations listed - updated August 2018)

Chen, M. S., Lin, C. Y., Chiu, Y. H., Chen, C. P., Tsai, P. J., & Wang, H. S. (2018). IL-1β-Induced Matrix Metalloprotease-1 Promotes Mesenchymal Stem Cell Migration via PAR1 and G-Protein-Coupled Signaling Pathway. Stem Cells International, 2018.
Yi, M. H., Kim, H. P., Jeong, K. Y., Kim, J. Y., Lee, I. Y., & Yong, T. S. (2018). Effects of the Th2-dominant milieu on allergic responses in Der f 1-activated mouse basophils and mast cells. Scientific reports, 8(1), 7706.
* SCH79797 and JNJ7777120 from Axon Medchem
Byskov, K., Boettger, T., Ruehle, P. F., Nielsen, N. V., Etscheid, M., & Kanse, S. M. (2017). Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells. Atherosclerosis, 265, 133-139.
*Vorapaxar and SCH79797 from Axon Medchem
White, M.J. and Gomer, R.H., 2015. Trypsin, Tryptase, and Thrombin Polarize Macrophages towards a Pro-Fibrotic M2a Phenotype. PloS one, 10(9), p.e0138748.
Shen, K., 2015. The Role of Activated Protein C in Bone, Arthritis, and Fracture Healing.

A Brief Exposure to Tryptase or Thrombin Potentiates Fibrocyte Differentiation in the Presence of Serum or Serum Amyloid.
White, M. J., Galvis-Carvajal, E., & Gomer, R. H. (2015).
P. J. Immunol. 2015, 194(1), 142-150.
* SCH79797 and Vorapaxar from Axon Medchem

Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor, K., van der Eerden, B. C., Jongwattanapisan, P., Roelofs, J. J., van Leeuwen, J. P., Bindels, R. J., & Hoenderop, J. G. (2015).
Bone, 2015, 72, 14-22. 

Activated protein C (APC) can increase bone anabolism via a protease‐activated receptor (PAR) 1/2 dependent mechanism.
Shen, K., Murphy, C. M., Chan, B., Kolind, M., Cheng, T. L., Mikulec, K., ... & Schindeler, A. (2014).
J. Ortho. Res. 32(12), 1549-1556. 

PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections
Riteau, B., & Khoufache, K. (2014).
U.S. Patent No. 20,140,308,296.

Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections.
Riteau, B., Guy B., Laetitia A., and Marie-eve H.
U.S. Patent 20,140,378,502, issued December 25, 2014.

Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model.
Aerts, L., Hamelin, M. È., Rhéaume, C., Lavigne, S., Couture, C., Kim, W., ... & Boivin, G. (2013).
PloS one, 8(8), e72529.
(* both SCH 79797 and SCH 530348 are procured from Axon Medchem)

Coagulation factor Xa induced an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. European Journal of Pharmacology.
Bukowska, A., Zacharias, I., Weinert, S., Skopp, K., Hartmann, C., Huth, C., & Goette, A. (2013).
Eur J Pharmacol. 2013 Oct 15;718(1-3):114-23. doi: 10.1016/j.ejphar.2013.09.006. Epub 2013 Sep 13.
(*SCH 79797 and GB 83 are procured from Axon Medchem)

PAR1 contributes to influenza A virus pathogenicity in mice.
Khoufache, K., Berri, F., Nacken, W., Vogel, A. B., Delenne, M., Camerer, E., ... & Riteau, B. (2013).
The Journal of clinical investigation, 123(1), 206.

Transient early neurotrophin release and delayed inflammatory cytokine release by microglia in response to PAR-2 stimulation.
Chen, C. W., Chen, Q. B., Ouyang, Q., Sun, J. H., Liu, F. T., Song, D. W., & Yuan, H. B. (2012).
Journal of Neuroinflammation, 9(1), 142.

Protease‐activated receptor 2, rather than protease‐activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis.
Xue, M., Chan, Y. K. A., Shen, K., Dervish, S., March, L., Sambrook, P. N., & Jackson, C. J. (2012).
Arthritis & Rheumatism, 64(1), 88-98.

Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.
Tudpor, K., Laínez, S., Kwakernaak, A. J., Kovalevskaya, N. V., Verkaart, S., van Genesen, S., ... & Hoenderop, J. G. (2012).
Journal of the American Society of Nephrology, 23(11), 1824.

Riteau, B., & Khoufache, K. (2012). U.S. Patent No. 20,120,213,802. Washington, DC: U.S. Patent and Trademark Office.

AERTS, L., Boivin, G., Hamelin, M. E., & Riteau, B. (2012). WIPO Patent Application PCT/CA2012/000455.

Riteau, B., & Khoufache, K. (2011). European Patent No. EP 2335717. Munich, Germany: European Patent Office.

Khoufache, K., & Riteau, B. (2010). European Patent Application 20100785378.

Riteau, B., & Khoufache, K. (2010). WIPO Patent Application PCT/EP2010/067516.

Khoufache, K., & Riteau, B. (2009). European Patent Application 20090306098.

Rivolta, C. M. N. (2008). WIPO Patent Application PCT/GB2008/050542.

(This is an incomplete list, updated in Jun-2016)

Please wait...